Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

C Sessa; J Balmaña; S L Bober; M J Cardoso; N Colombo; G Curigliano; S M Domchek; D G Evans; D Fischerova; N Harbeck; C Kuhl; B Lemley; E Levy-Lahad; M Lambertini; J A Ledermann; S Loibl; K-A Phillips; S Paluch-Shimon; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

doi:10.1016/j.annonc.2022.10.004

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Ann Oncol. 2023 Jan;34(1):33-47. doi: 10.1016/j.annonc.2022.10.004. Epub 2022 Oct 25.

Authors

C Sessa¹, J Balmaña², S L Bober³, M J Cardoso⁴, N Colombo⁵, G Curigliano⁶, S M Domchek⁷, D G Evans⁸, D Fischerova⁹, N Harbeck¹⁰, C Kuhl¹¹, B Lemley¹², E Levy-Lahad¹³, M Lambertini¹⁴, J A Ledermann¹⁵, S Loibl¹⁶, K-A Phillips¹⁷, S Paluch-Shimon¹⁸; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Affiliations

¹ Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
² Medical Oncology Hospital Vall d'Hebron and Hereditary Cancer Genetics Group, Vall d'Hebron Institut of Oncology, Barcelona, Spain.
³ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute/Harvard Medical School, Boston, USA.
⁴ Champalimaud Foundation, Breast Unit and Faculdade de Medicina, Lisbon, Portugal.
⁵ Department of Gynecologic Oncology, Istituto Europeo di Oncologia e IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
⁶ Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
⁷ Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
⁸ Manchester Centre for Genomic Medicine, Division of Evolution Infection and Genomic Sciences, University of Manchester, MAHSC, Manchester, UK; Manchester Centre for Genomic Medicine, MAHSC, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
⁹ Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
¹⁰ Breast Center, Department of Obstetrics & Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany.
¹¹ Department of Diagnostic and Interventional Radiology, University Hospital Aachen, University Hospital Aachen (UKA), RWTH Aachen, Germany.
¹² KIU - Patient Organisation for Women with Gynaecological Cancer, Copenhagen, Denmark; Clinical Trials Project, ESGO ENGAGe, Prague, Czech Republic.
¹³ Medical Genetics Institute, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
¹⁴ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
¹⁵ Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK.
¹⁶ GBG Forschungs GmbH, Neu-Isenburg, Germany.
¹⁷ Department of Medical Oncology, Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
¹⁸ Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel.

PMID: 36307055
DOI: 10.1016/j.annonc.2022.10.004

No abstract available

Keywords: BRCA; ESMO Clinical Practice Guideline; hereditary breast and ovarian cancer syndromes; risk reduction.

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms* / diagnosis
Breast Neoplasms* / genetics
Breast Neoplasms* / prevention & control
Early Detection of Cancer
Female
Genetic Predisposition to Disease
Humans
Neoplastic Syndromes, Hereditary*
Ovarian Neoplasms* / diagnosis
Ovarian Neoplasms* / epidemiology
Ovarian Neoplasms* / genetics
Risk Reduction Behavior

Supplementary concepts

Breast Cancer, Familial